These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 34592177)

  • 1. Inappropriate censoring in Kaplan-Meier analyses.
    Fojo T; Simon RM
    Lancet Oncol; 2021 Oct; 22(10):1358-1360. PubMed ID: 34592177
    [No Abstract]   [Full Text] [Related]  

  • 2. Censored patients in Kaplan-Meier plots of cancer drugs: An empirical analysis of data sharing.
    Rosen K; Prasad V; Chen EY
    Eur J Cancer; 2020 Dec; 141():152-161. PubMed ID: 33160265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methods to Analyse Time-to-Event Data: The Kaplan-Meier Survival Curve.
    D'Arrigo G; Leonardis D; Abd ElHafeez S; Fusaro M; Tripepi G; Roumeliotis S
    Oxid Med Cell Longev; 2021; 2021():2290120. PubMed ID: 34594473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hidden Imputations and the Kaplan-Meier Estimator.
    Cole SR; Edwards JK; Naimi AI; Muñoz A
    Am J Epidemiol; 2020 Nov; 189(11):1408-1411. PubMed ID: 32412079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kaplan-Meier Survival, Actuarial Survival, Censoring, and Competing Events-What Is What?
    Hage A; Hage F
    Ann Thorac Surg; 2022 Jul; 114(1):40-43. PubMed ID: 35367199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonparametric estimation of a multivariate distribution in the presence of censoring.
    Hanley JA; Parnes MN
    Biometrics; 1983 Mar; 39(1):129-39. PubMed ID: 6871341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.
    Lueza B; Rotolo F; Bonastre J; Pignon JP; Michiels S
    BMC Med Res Methodol; 2016 Mar; 16():37. PubMed ID: 27025706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kaplan-Meier survival curves.
    Hess AS; Hess JR
    Transfusion; 2020 Apr; 60(4):670-672. PubMed ID: 32077507
    [No Abstract]   [Full Text] [Related]  

  • 9. The Human Cancer Pathology Atlas: An open-access source for more than 900,000 Kaplan-Meier plots and 5 million cancer tissue images.
    El Bairi K; Amrani M; Afqir S
    Biomed Pharmacother; 2017 Dec; 96():1438-1439. PubMed ID: 29055506
    [No Abstract]   [Full Text] [Related]  

  • 10. Informative censoring in relative survival.
    Rebolj Kodre A; Pohar Perme M
    Stat Med; 2013 Nov; 32(27):4791-802. PubMed ID: 23761182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies.
    Jain RK; Lee JJ; Ng C; Hong D; Gong J; Naing A; Wheler J; Kurzrock R
    J Clin Oncol; 2012 Jul; 30(21):2684-90. PubMed ID: 22689801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detecting overall survival benefit derived from survival postprogression rather than progression-free survival.
    Morita S; Sakamaki K; Yin G
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25956357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weighted Kaplan-Meier estimators motivating to estimate HIV-1 RNA reduction censored by a limit of detection.
    Ahmed I; Flandre P
    Stat Med; 2020 Mar; 39(7):968-983. PubMed ID: 31981243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doubly robust estimator of risk in the presence of censoring dependent on time-varying covariates: application to a primary prevention trial for coronary events with pravastatin.
    Kawahara T; Shinozaki T; Matsuyama Y
    BMC Med Res Methodol; 2020 Jul; 20(1):204. PubMed ID: 32736528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival analysis.
    Kim J
    Pediatr Rev; 2012 Apr; 33(4):172-4. PubMed ID: 22474114
    [No Abstract]   [Full Text] [Related]  

  • 16. Measures of follow-up in time-to-event studies: Why provide them and what should they be?
    Betensky RA
    Clin Trials; 2015 Aug; 12(4):403-8. PubMed ID: 26025565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation of colorectal adenoma recurrence with dependent censoring.
    Hsu CH; Long Q; Alberts DS
    BMC Med Res Methodol; 2009 Sep; 9():66. PubMed ID: 19788750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapies in clinical trials: do they demand different evaluation tools?
    Tuma RS
    J Natl Cancer Inst; 2011 May; 103(10):780-1. PubMed ID: 21551417
    [No Abstract]   [Full Text] [Related]  

  • 19. Correcting for dependent censoring in routine outcome monitoring data by applying the inverse probability censoring weighted estimator.
    Willems S; Schat A; van Noorden MS; Fiocco M
    Stat Methods Med Res; 2018 Feb; 27(2):323-335. PubMed ID: 26988930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison between Kaplan-Meier and weighted Kaplan-Meier methods of five-year survival estimation of patients with gastric cancer.
    Zare A; Mahmoodi M; Mohammad K; Zeraati H; Hosseini M; Holakouie Naieni K
    Acta Med Iran; 2014; 52(10):764-7. PubMed ID: 25369011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.